How a Cholesterol-Lowering Medication Could Reduce Heart Attack Risk
A recent study conducted at Cedars-Sinai Medical Center sheds light on how evolocumab, a drug that significantly lowers cholesterol, may help prevent heart attacks in individuals with coronary artery disease. Coronary artery disease occurs when cholesterol deposits accumulate along the walls of heart arteries, leading to the formation of plaques. These plaques often start as inflammatory regions, and as they grow, they become susceptible to rupture, potentially causing a heart attack.
Evolocumab belongs to a class of medications known as PCSK9 inhibitors, which are highly effective at reducing bad cholesterol levels in the blood. The study focused on patients with substantial noncalcified plaque buildup, a type of softer, more rupture-prone plaque considered at higher risk than calcified variants.
To assess the drug's impact, researchers utilized advanced imaging techniques such as positron emission tomography (PET) with radioactive sodium fluoride and coronary computed tomography angiography (CCTA), coupled with new artificial intelligence tools to measure inflammation and plaque volume. Patients received evolocumab, and after 18 months, scans revealed a significant reduction in inflammation and plaque size.
Dr. Daniel S. Berman, the study’s lead investigator, emphasized that beyond cholesterol reduction, evolocumab appears to lower arterial inflammation—a key factor in plaque instability. This inflammation decrease could be a crucial mechanism by which the drug reduces the risk of heart attacks.
The findings suggest that PCSK9 inhibitors like evolocumab not only control cholesterol levels but might also directly stabilize vulnerable plaques within the coronary arteries, providing a dual benefit in cardiovascular disease management.
This research advances our understanding of how targeted therapies can mitigate heart attack risk and highlights the importance of inflammation in coronary artery disease development. Further studies are ongoing to confirm and expand these results.
Source: https://medicalxpress.com/news/2025-05-cholesterol-drug-heart.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Group Prenatal Care Model Enhances Satisfaction, Support, and Trust Among Expectant Mothers
A Rutgers University study demonstrates that group prenatal care improves maternal satisfaction, trust, and support, contributing to better pregnancy outcomes and reduced disparities.
Combination Therapy Shows Promise and Safety for Specific Genetic Types of Acute Myeloid Leukemia
New clinical research indicates that combining standard AML treatment with targeted drugs like revumenib offers high remission rates and safety for patients with specific genetic mutations, paving the way for personalized therapy approaches.
Insights into the Early Stages of Lung Fibrosis Through Tissue Stiffening
New research reveals how tissue stiffening in the lungs can be a key early indicator and trigger of fibrosis, opening doors for earlier diagnosis and intervention.
Advanced Multimodal Deep Learning Enhances Risk Prediction for Cervical Cancer Radiotherapy
A groundbreaking multimodal deep learning model significantly improves risk prediction in cervical cancer radiotherapy, enabling personalized treatment decisions and better outcomes.